Altered splicing of ATG16‐L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non‐small cell lung cancer

Altered splicing of ATG16‐L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non‐small cell lung cancer

Despite the initial efficacy of using tyrosine kinase inhibitors of epidermal growth factor receptors (EGFR‐TKIs) for treating patients with non‐small cell lung cancer (NSCLC), resistance inevitably develops. Recent studies highlight a link between alternative splicing and cancer drug response. Ther...

Full description

Bibliographic Details
Main Authors: Anne‐Sophie Hatat, Clara Benoit‐Pilven, Amélie Pucciarelli, Florence deFraipont, Lucie Lamothe, Pascal Perron, Amandine Rey, Matteo Giaj Levra, Anne‐Claire Toffart, Didier Auboeuf, Beatrice Eymin, Sylvie Gazzeri
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:Molecular Oncology
Subjects:
ATG16‐L1
autophagy
EGFR‐TKI
non‐small cell lung cancer
resistance
Online Access:https://doi.org/10.1002/1878-0261.13229

Internet

https://doi.org/10.1002/1878-0261.13229

Similar Items